Login to Your Account



Clinic Roundup


Monday, August 22, 2011
Cytokinetics Inc., of South San Francisco, said The Lancet published results from two studies supporting the use of omecamtiv mecarbil in heart failure.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription